Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a $13.00 price objective by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 109.00% from the company’s current price.

INO has been the topic of a number of other research reports. Aegis restated a “buy” rating and issued a $14.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Citigroup Inc. assumed coverage on shares of Inovio Pharmaceuticals in a research note on Friday, October 6th. They issued a “buy” rating and a $10.00 price objective for the company. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 18th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $19.98.

Shares of Inovio Pharmaceuticals (NASDAQ INO) traded down 0.242% during trading on Tuesday, hitting $6.195. The stock had a trading volume of 68,324 shares. The firm has a 50-day moving average of $6.18 and a 200 day moving average of $6.65. Inovio Pharmaceuticals has a 1-year low of $5.28 and a 1-year high of $9.86. The company’s market capitalization is $558.96 million.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The company had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. During the same quarter in the prior year, the business posted ($0.26) EPS. The firm’s revenue was up 229.2% compared to the same quarter last year. Equities research analysts predict that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (INO) Given a $13.00 Price Target by HC Wainwright Analysts” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/17/inovio-pharmaceuticals-inc-ino-given-buy-rating-at-hc-wainwright.html.

A number of large investors have recently bought and sold shares of INO. Wells Fargo & Company MN grew its position in shares of Inovio Pharmaceuticals by 28.9% during the 1st quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after acquiring an additional 27,898 shares during the period. Bank of New York Mellon Corp grew its position in shares of Inovio Pharmaceuticals by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after acquiring an additional 11,765 shares during the period. American International Group Inc. grew its position in shares of Inovio Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 2,695 shares during the period. Teachers Advisors LLC grew its position in shares of Inovio Pharmaceuticals by 2.3% during the 1st quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 3,411 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Inovio Pharmaceuticals by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after acquiring an additional 226,861 shares during the period. Hedge funds and other institutional investors own 24.83% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.